ProfileGDS5678 / 1431920_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 5% 5% 5% 5% 6% 5% 5% 5% 5% 5% 5% 6% 5% 5% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.08555
GSM967853U87-EV human glioblastoma xenograft - Control 22.085015
GSM967854U87-EV human glioblastoma xenograft - Control 32.08175
GSM967855U87-EV human glioblastoma xenograft - Control 42.047375
GSM967856U87-EV human glioblastoma xenograft - Control 52.068646
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.117995
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.096625
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.065565
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.068465
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.079235
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.07385
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.074166
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.080085
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.077195